Entellus Medical Inc (NASDAQ:ENTL) has been assigned an average recommendation of “Hold” from the seven brokerages that are currently covering the company. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $22.25.
A number of research firms recently issued reports on ENTL. Canaccord Genuity reissued a “buy” rating and issued a $21.00 price objective on shares of Entellus Medical in a report on Tuesday, December 20th. BTIG Research downgraded shares of Entellus Medical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 22nd. Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $21.00 price objective on the stock in a report on Monday, January 9th. Piper Jaffray Companies reissued a “positive” rating on shares of Entellus Medical in a report on Wednesday, December 14th. Finally, Guggenheim began coverage on shares of Entellus Medical in a report on Tuesday, December 6th. They issued a “buy” rating and a $25.00 price objective on the stock.
In other Entellus Medical news, VP Karen E. Peterson sold 10,160 shares of Entellus Medical stock in a transaction that occurred on Wednesday, January 4th. The shares were sold at an average price of $18.74, for a total transaction of $190,398.40. Following the transaction, the vice president now owns 43,384 shares of the company’s stock, valued at $813,016.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian E. Farley sold 9,842 shares of Entellus Medical stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $19.11, for a total transaction of $188,080.62. Following the transaction, the director now directly owns 449,423 shares in the company, valued at approximately $8,588,473.53. The disclosure for this sale can be found here. Insiders have sold 607,096 shares of company stock worth $10,490,234 in the last ninety days. Insiders own 9.10% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Arrowpoint Asset Management LLC increased its position in shares of Entellus Medical by 39.9% in the fourth quarter. Arrowpoint Asset Management LLC now owns 312,634 shares of the medical technology company’s stock valued at $5,931,000 after buying an additional 89,158 shares in the last quarter. Wasatch Advisors Inc. increased its position in shares of Entellus Medical by 10.0% in the third quarter. Wasatch Advisors Inc. now owns 199,731 shares of the medical technology company’s stock valued at $4,430,000 after buying an additional 18,150 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Entellus Medical by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 17,025 shares of the medical technology company’s stock valued at $312,000 after buying an additional 210 shares in the last quarter. Millrace Asset Group Inc. purchased a new position in shares of Entellus Medical during the fourth quarter valued at $1,252,000. Finally, Perkins Capital Management Inc. increased its position in shares of Entellus Medical by 119.8% in the third quarter. Perkins Capital Management Inc. now owns 49,450 shares of the medical technology company’s stock valued at $1,097,000 after buying an additional 26,950 shares in the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.
Entellus Medical (NASDAQ:ENTL) opened at 13.83 on Monday. Entellus Medical has a one year low of $12.31 and a one year high of $22.63. The company’s market cap is $302.56 million. The stock has a 50 day moving average of $15.12 and a 200-day moving average of $18.25.
Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Tuesday, February 21st. The medical technology company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.06. The business earned $21.70 million during the quarter, compared to analysts’ expectations of $21.58 million. Entellus Medical had a negative return on equity of 53.20% and a negative net margin of 36.91%. The business’s quarterly revenue was up 20.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.27) EPS. On average, equities analysts predict that Entellus Medical will post ($1.27) EPS for the current fiscal year.
Your IP Address:
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/entellus-medical-inc-entl-given-consensus-rating-of-hold-by-analysts/1708782.html
Receive News & Ratings for Entellus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.